RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:454723

Endometrioid carcinoma of ovary

high confidenceDisorder

Publications

18,422

98.7th percentile

Trials

66

Interventional, condition-specific

Researchers

1,557

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare malignant epithelial tumor of ovary characterized by confluent or cribriform proliferations of round, oval, or tubular glands, typically lined by stratified non-mucin-containing epithelium with well-defined luminal margins. Squamous differentiation, secretory changes, oxyphilic variants, sex cord-stromal type patterns, or sertoliform endometrioid carcinomas may occur. Patients most commonly present in the sixth decade of life, either with a pelvic mass with or without pain, or without any symptoms. The tumor may be bilateral and is frequently associated with endometriosis and/or endometrial carcinoma.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (12)

endometrioid adenocarcinoma of ovary · endometrioid adenocarcinoma of the ovary · endometrioid cancer of ovary · endometrioid cancer of the ovary · endometrioid carcinoma of ovary · endometrioid carcinoma of the ovary · endometrioid ovary carcinoma · endometrium adenocarcinoma of ovary · ovarian endometrioid adenocarcinoma · ovarian endometrioid cancer · ovarian endometrioid carcinoma · ovary endometrium adenocarcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    18,422 matched papers (11,196 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    66 matched on ClinicalTrials.gov (9 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

18,422

18,422 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

18,422 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

11,196 in the last 10 years · high confidence · 98.7th percentile (publications denominator)

Phrase hits: 18,422 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,557

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y8 papers · 2026

    Department of Gynecology, Hebei General Hospital, Shijiazhuang, China.

    Papers in Europe PMC
  2. 02
    Li Y7 papers · 2026

    Department of Laboratory Medicine, Tinglin Hospital of Jinshan District, Shanghai, 201505, People's Republic of China.

    Papers in Europe PMC
  3. 03
    Wang L7 papers · 2026

    Department of Hematology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, Shanghai, People's Republic of China.

    Papers in Europe PMC
  4. 04
    Wang X7 papers · 2026

    Department of Gynecology, Hebei General Hospital, Shijiazhuang, China.

    Papers in Europe PMC
  5. 05
    Liu Y6 papers · 2026

    School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.

    Papers in Europe PMC
  6. 06
    Zhang J6 papers · 2026

    Department of Obstetrics and Gynecology, University of Vermont Medical Center, Burlington, VT, USA.

    Papers in Europe PMC
  7. 07
    Chen Y4 papers · 2026

    Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, College of Basic Medical Science, Dalian Medical University, Dalian, Liaoning, China.

    Papers in Europe PMC
  8. 08
    Li J4 papers · 2026

    Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China.

    Papers in Europe PMC
  9. 09
    Liu J4 papers · 2026

    School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. liujy@wyu.edu.cn.

    Papers in Europe PMC
  10. 10
    Liu X4 papers · 2026

    Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

66

interventional trials for this specific condition

66 interventional trials matched this specific condition name; 9 currently recruiting in our sample.

Data as of 27 July 2026

66 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.7th percentile).

high confidence · 97.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

66 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Endometrioid carcinoma of ovary" OR "Endometrioid carcinoma of the ovary" OR "endometrioid adenocarcinoma of ovary" OR "endometrioid adenocarcinoma of the ovary" OR "endometrioid cancer of ovary" OR "endometrioid cancer of the ovary" OR "endometrioid ovary carcinoma" OR "endometrium adenocarcinoma of ovary" OR "endometrium adenocarcinoma of the ovary" OR "ovarian endometrioid adenocarcinoma" OR "ovarian endometrioid cancer" OR "ovarian endometrioid carcinoma" OR "ovary endometrium adenocarcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Endometrioid carcinoma of ovary" OR "Endometrioid carcinoma of the ovary" OR "endometrioid adenocarcinoma of ovary" OR "endometrioid adenocarcinoma of the ovary" OR "endometrioid cancer of ovary" OR "endometrioid cancer of the ovary" OR "endometrioid ovary carcinoma" OR "endometrium adenocarcinoma of ovary" OR "endometrium adenocarcinoma of the ovary" OR "ovarian endometrioid adenocarcinoma" OR "ovarian endometrioid cancer" OR "ovarian endometrioid carcinoma" OR "ovary endometrium adenocarcinoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 66 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T16:42:53.153Z